Effects of Long-Acting GLP-1 (Glucagon-like Peptide-1) or Dual Incretin (GLP-1 and GIP [Glucose-dependent Insulinotropic Peptide]) Modulation on Gastric Motor Functions

NCT06801015 on ClinicalTrials.gov · last registry update 2025-12-26

A small phase 4 — 30 participants, against a typical 75. Due to report 31 January 2028, alongside 25 other tracked readouts that quarter. Primary outcome, as filed: Gastric emptying of solids T1/2 min, that is time for half meal to empty from stomach. Sponsors move these dates routinely; any movement since this site started watching is listed below. semaglutide is already approved in the US for obesity, so this is asking a further question rather than establishing the drug works at all.

Status: ACTIVE_NOT_RECRUITING
Phase: P4
Drug: semaglutide
Ozempic, Rybelsus, Wegovy
Sponsor: Mayo Clinic
Sponsor type: Other
Enrollment: 30
Started: 2025-10-01
Primary completion: 2028-01-31 estimated

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Gastric emptying of solids T1/2 min, that is time for half meal to empty from stomach

Conditions studied

Obesity

Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.